There was an increase in life expectancy between 2021 and 2023 across all racial and ethnic groups. American Indian and Alaska Native (AIAN) people experienced the largest increase in life expectancy of 4.5 years during this time, followed by Hispanic (3.5 years) and Black people (2.8 years).
A KFF survey of state Medicaid officials examines state Medicaid and CHIP eligibility, enrollment, and renewal policies in place as of January 2025 as states return to routine operations following the unwinding of the continuous enrollment provision. The survey finds that states have broadly adopted policy and system changes to automate and improve the accuracy…
We’re stepping into a moment that will undoubtedly redefine care delivery across the medical landscape — it’s one we can’t afford to fumble. The post Healthcare’s Next Chapter: Agentic AI Meets Human-Centric Innovation appeared first on MedCity News.
Cybersecurity experts predict cybersecurity attacks will continue to happen with more sophistication
Cemdisiran, a small interfering RNA drug that Regeneron Pharmaceuticals licensed from Alnylam Pharmaceuticals, met the goals of its pivotal test in generalized myasthenia gravis. The rare neuromuscular disease has several new therapies, but analysts see cemdisiran as having advantages over one particular class of drugs. The post Regeneron’s RNA Med for Muscle Disease Meets Trial…
Along with the occasional aches and pains, growing older can bring surprise setbacks and serious diseases. Longtime relationships with doctors people trust often make even bad news more tolerable. Losing that support — especially during a health crisis — can be terrifying. That’s why little-known federal requirements are supposed to protect people with privately run…
By MIKE MAGEE In case you’ve missed it, sleep is all the rage in neurosciences these days. They are fast at work rebranding it “the brain’s rinse cycle.” The brain, protectively encased in an unyielding bony casing, lacks the delicate lymphatic system that transports used body metabolites to breakdown and extraction sites in all other parts…
The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist. The post Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to…